Sun Pharma Leadership Changes & USFDA Inspection Update

  Published 11 months ago

Sun Pharma announces MD change, Dilip Shanghvi to executive chairman, Kirti Ganorkar appointed; USFDA issues Form 483 after inspection.

  • Dilip Shanghvi transitions to executive chairman, focusing on specialty portfolio growth and strategic oversight.
  • Kirti Ganorkar, a 27-year veteran, led India business growth, expanded specialty drugs, and global markets.
  • USFDA inspects Gujarat facility, issues Form 483 with 8 observations post June 2025 inspection.
You might like these

JLR Sales Fall: Cyber, Tariffs, Jaguar

Hindalco Q4 Beats, Faces Headwinds

India's Strong 2025 Growth Outlook

Mahindra SUV Sales Jump 20% in July

Enviro Infra Wins ₹395 Cr Project

Tariff Shock: US Output Down, Prices Up

India, Fiji Climate, Trade & Biofuel Pact

News that matters the most ⚡